300
Participants
Start Date
April 30, 2020
Primary Completion Date
August 31, 2020
Study Completion Date
December 31, 2020
RBA-2
Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
Tampa General Hospital, Tampa
University of South Florida, Tampa
AdventHealth Tampa, Tampa
Lead Sponsor
University of South Florida
OTHER
Kaligia Biosciences, LLC
INDUSTRY